Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Crystallographic and electrophilic fragment screening of the SARS-CoV-2 main protease
A. Douangamath, D. Fearon, Paul Gehrtz, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 486

Showing 1-25 of 486 citing articles:

The SARS-CoV-2 main protease as drug target
Sven Ullrich, Christoph Nitsche
Bioorganic & Medicinal Chemistry Letters (2020) Vol. 30, Iss. 17, pp. 127377-127377
Open Access | Times Cited: 719
Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19
Yuto Unoh, Shota Uehara, Kenji Nakahara, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 9, pp. 6499-6512
Open Access | Times Cited: 441
Structural biology of SARS-CoV-2 and implications for therapeutic development
Haitao Yang, Zihe Rao
Nature Reviews Microbiology (2021) Vol. 19, Iss. 11, pp. 685-700
Open Access | Times Cited: 416
Structural Basis of Potential Inhibitors Targeting SARS-CoV-2 Main Protease
Hylemariam Mihiretie Mengist, Tebelay Dilnessa, Tengchuan Jin
Frontiers in Chemistry (2021) Vol. 9
Open Access | Times Cited: 284
Potent Noncovalent Inhibitors of the Main Protease of SARS-CoV-2 from Molecular Sculpting of the Drug Perampanel Guided by Free Energy Perturbation Calculations
Chunhui Zhang, Elizabeth A. Stone, M.G. Deshmukh, et al.
ACS Central Science (2021) Vol. 7, Iss. 3, pp. 467-475
Open Access | Times Cited: 231
Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site
Jaeyong Lee, L.J. Worrall, M. Vuckovic, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 212
Inhibition mechanism of SARS-CoV-2 main protease by ebselen and its derivatives
Kangsa Amporndanai, Xiaoli Meng, Weijuan Shang, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 206
Ultralarge Virtual Screening Identifies SARS-CoV-2 Main Protease Inhibitors with Broad-Spectrum Activity against Coronaviruses
Andreas Luttens, Hjalmar Gullberg, Eldar Abdurakhmanov, et al.
Journal of the American Chemical Society (2022) Vol. 144, Iss. 7, pp. 2905-2920
Open Access | Times Cited: 186
Leveraging the antiviral type I interferon system as a first line of defense against SARS-CoV-2 pathogenicity
Daisy A. Hoagland, Rasmus Møller, Skyler Uhl, et al.
Immunity (2021) Vol. 54, Iss. 3, pp. 557-570.e5
Open Access | Times Cited: 184
Fragment binding to the Nsp3 macrodomain of SARS-CoV-2 identified through crystallographic screening and computational docking
M. Schuller, G.J. Correy, Stefan Gahbauer, et al.
Science Advances (2021) Vol. 7, Iss. 16
Open Access | Times Cited: 161
The SARS‐CoV‐2 main protease (Mpro): Structure, function, and emerging therapies for COVID‐19
Qing Hu, Yuan Xiong, Guanghao Zhu, et al.
MedComm (2022) Vol. 3, Iss. 3
Open Access | Times Cited: 148
Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity
Chunlong Ma, Zilei Xia, M. Sacco, et al.
Journal of the American Chemical Society (2021) Vol. 143, Iss. 49, pp. 20697-20709
Open Access | Times Cited: 122
Crystal structure of SARS-CoV-2 Orf9b in complex with human TOM70 suggests unusual virus-host interactions
Xiaopan Gao, Kaixiang Zhu, Bo Qin, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 108
Structure-Based Optimization of ML300-Derived, Noncovalent Inhibitors Targeting the Severe Acute Respiratory Syndrome Coronavirus 3CL Protease (SARS-CoV-2 3CLpro)
Sang Hoon Han, Christopher M. Goins, T. Arya, et al.
Journal of Medicinal Chemistry (2021) Vol. 65, Iss. 4, pp. 2880-2904
Open Access | Times Cited: 107
Fragment-based covalent ligand discovery
Wenchao Lu, Milka Kostić, Tinghu Zhang, et al.
RSC Chemical Biology (2021) Vol. 2, Iss. 2, pp. 354-367
Open Access | Times Cited: 106
Accelerating antiviral drug discovery: lessons from COVID-19
Annette von Delft, Matthew D. Hall, Ann D. Kwong, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 7, pp. 585-603
Open Access | Times Cited: 98
Open science discovery of potent noncovalent SARS-CoV-2 main protease inhibitors
Melissa L. Boby, D. Fearon, Matteo P. Ferla, et al.
Science (2023) Vol. 382, Iss. 6671
Open Access | Times Cited: 88
Structural basis of nirmatrelvir and ensitrelvir activity against naturally occurring polymorphisms of the SARS-CoV-2 main protease
G.D. Noske, Ellen de Souza Silva, Mariana Ortiz de Godoy, et al.
Journal of Biological Chemistry (2023) Vol. 299, Iss. 3, pp. 103004-103004
Open Access | Times Cited: 81
Fragment‐based drug discovery—the importance of high‐quality molecule libraries
Marta Bon, Alan Bilsland, Justin Bower, et al.
Molecular Oncology (2022) Vol. 16, Iss. 21, pp. 3761-3777
Open Access | Times Cited: 76
Inhibition of the main protease of SARS-CoV-2 (Mpro) by repurposing/designing drug-like substances and utilizing nature’s toolbox of bioactive compounds
Io Antonopoulou, Eleftheria Sapountzaki, Ulrika Rova, et al.
Computational and Structural Biotechnology Journal (2022) Vol. 20, pp. 1306-1344
Open Access | Times Cited: 70
Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine
Lennart Brewitz, Leo Dumjahn, Yilin Zhao, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 4, pp. 2663-2680
Open Access | Times Cited: 49
Emerging and Re-emerging Warheads for Targeted Covalent Inhibitors: An Update
Laura Hillebrand, Xiaojun Julia Liang, Ricardo A. M. Serafim, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 10, pp. 7668-7758
Closed Access | Times Cited: 48
Room-temperature crystallography reveals altered binding of small-molecule fragments to PTP1B
Tamar Mehlman, J.T. Biel, Syeda Maryam Azeem, et al.
eLife (2023) Vol. 12
Open Access | Times Cited: 44
Folding@home: Achievements from over 20 years of citizen science herald the exascale era
Vincent A. Voelz, Vijay S. Pande, Gregory R. Bowman
Biophysical Journal (2023) Vol. 122, Iss. 14, pp. 2852-2863
Open Access | Times Cited: 41
Multiple redox switches of the SARS-CoV-2 main protease in vitro provide opportunities for drug design
Lisa-Marie Funk, Gereon Poschmann, Fabian Rabe von Pappenheim, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 16
Page 1 - Next Page

Scroll to top